Genital ulcer disease can be caused by a wide variety of sources. Most commonly, genital ulcer disease is grouped into infectious and noninfectious causes. HSV, syphilis, lymphogranuloma venereum, and chancroid represent some common infectious ulcers. Noninfectious causes on the other hand can be inflammatory, noninflammatory, or malignant (eg, squamous cell carcinoma). Depending on the etiology, genital ulcers may present with unique features that can help clinicians identify the etiology and start treatment in a timely manner. The clinical presentation and management of infectious and noninfectious genital ulcers will be discussed in this review.
CoreyLAdamsHGBrownZAHolmesKK.Genital herpes simplex virus infections: clinical manifestations, course, and complications. Ann Intern Med. 1983;98(6):958-972. doi:10.7326/0003-4819-98-6-958
7.
BenedettiJCoreyLAshleyR.Recurrence rates in genital herpes after symptomatic first-episode infection. Ann Intern Med. 1994;121(11):847-854. doi:10.7326/0003-4819-121-11-199412010-00004
8.
WorkowskiKABolanGA; Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015;64(RR-03):1-137.
World Health Organization. Department of HIV/AIDS. Global Prevalence and Incidence of Selected Curable Sexually Transmitted Infections: Overview and Estimates. Geneva, Switzerland: WHO; 2001:50.
11.
ChoudhriYMillerJSandhuJLeonAAhoJ.Infectious and congenital syphilis in Canada, 2010-2015. Can Commun Dis Rep. 2018;44(2):43-48. doi:10.14745/ccdr.v44i02a02
SatoNSde MeloCSZerbiniLCSilveiraEPFagundesLJUedaM.Assessment of the rapid test based on an immunochromatography technique for detecting anti-Treponema pallidum antibodies. Rev Inst Med Trop Sao Paulo. 2003;45(6):319-322. doi:10.1590/S0036-46652003000600004
14.
CoxDLChangPMcDowallAWRadolfJD.The outer membrane, not a coat of host proteins, limits antigenicity of virulentTreponema pallidum. Infect Immun. 1992;60(3):1076-1083.
15.
StammLV.Syphilis: re-emergence of an old foe. Microb Cell. 2016;3(9):363-370. doi:10.15698/mic2016.09.523
16.
KalasapuraRRYadavDKJainSK.Multiple primary penile chancre: a re-emphasize. Indian J Sex Transm Dis AIDS. 2014;35(1):71-73. doi:10.4103/2589-0557.132410
LewisDA.Epidemiology, clinical features, diagnosis and treatment of Haemophilus ducreyi – a disappearing pathogen?Expert Rev Anti Infect Ther. 2014;12(6):687-696. doi:10.1586/14787210.2014.892414
MabeyDPeelingRW.Lymphogranuloma venereum. Sex Transm Infect. 2002;78(2):90-92. doi:10.1136/sti.78.2.90
24.
TottenSMacLeanRPayneESeveriniA.Chlamydia and lymphogranuloma venereum in Canada: 2003-2012 summary report. Can Commun Dis Rep. 2015;41(2):20-25. doi:10.14745/ccdr.v41i02a01
25.
Van der BijAKSpaargarenJMorréSAet al. Diagnostic and clinical implications of anorectal lymphogranuloma venereum in men who have sex with men: a retrospective case-control study. Clin Infect Dis. 2006;42(2):186-194. doi:10.1086/498904
26.
PapagrigoriadisSRennieJA.Lymphogranuloma venereum as a cause of rectal strictures. Postgrad Med J. 1998;74(869):168-169. doi:10.1136/pgmj.74.869.168
27.
LynchCMFelderTLSchwandtRAShashyRG.Lymphogranuloma venereum presenting as a rectovaginal fistula. Infect Dis Obstet Gynecol. 1999;7(4):199-201. doi:10.1002/(SICI)1098-0997(1999)7:4<199::AID-IDOG7>3.0.CO;2-K
28.
FarhiDWendlingJMolinariEet al. Non-sexually related acute genital ulcers in 13 pubertal girls: a clinical and microbiological study. Arch Dermatol. 2009;145(1):38-45. doi:10.1001/archdermatol.2008.519
29.
Vieira-BaptistaPLima-SilvaJBeiresJMartinez-de-OliveiraJ.Lipschütz ulcers: should we rethink this? An analysis of 33 cases. Eur J Obstet Gynecol Reprod Biol. 2016;198:149-152. doi:10.1016/j.ejogrb.2015.07.016
Di LerniaVMansouriY. Epstein-Barr virus and skin manifestations in childhood. Int J Dermatol. 2013;52(10):1177-1184. doi:10.1111/j.1365-4632.2012.05855.x.
32.
LehmanJSBruceAJWetterDAFergusonSBRogersRS.Reactive nonsexually related acute genital ulcers: review of cases evaluated at Mayo Clinic. J Am Acad Dermatol. 2010;63(1):44-51. doi:10.1016/j.jaad.2009.08.038
33.
JerdanKAronsonIHernandezCFishmanPMGrothJV.Genital ulcers associated with Epstein-Barr virus. Cutis. 2013;91(6):273-276.
34.
Hernández-NúñezACórdobaSRomero-MatéAMiñanoRSanzTBorbujoJ.Lipchütz ulcers – four cases. Pediatr Dermatol. 2008;25(3):364-367. doi:10.1111/j.1525-1470.2008.00684.x
35.
HalvorsenJABrevigTAasTSkarAGSlevoldenEMMoiH.Genital ulcers as initial manifestation of Epstein-Barr virus infection: two new cases and a review of the literature. Acta Derm Venereol. 2006;86(5):439-442. doi:10.2340/00015555-0140
36.
TaylorSDrakeSMDedicoatMWoodMJ.Genital ulcers associated with acute Epstein-Barr virus infection. Sex Transm Infect. 1998;74(4):296-297. doi:10.1136/sti.74.4.296
37.
WetterDABruceAJMacLaughlinKLRogersRSIII. Ulcus vulvae acutum in a 13-year-old girl after influenza A infection. Skinmed. 2008;7(2):95-98. doi:10.1111/j.1751-7125.2008.07273.x
HuppertJS.Lipschutz ulcers: evaluation and management of acute genital ulcers in women. Dermatol Ther. 2010;23(5):533-540. doi:10.1111/j.1529-8019.2010.01356.x
41.
WylesSPLehmanJSLohseCMBruceAJTorgersonRR.Recurrence of genital aphthosis in girls: a retrospective analysis. J Am Acad Dermatol. 2017;77(5):982-984. doi:10.1016/j.jaad.2017.06.046
42.
BandowGD.Diagnosis and management of vulvar ulcers. Dermatol Clin. 2010;28(4):753-763. doi:10.1016/j.det.2010.08.008
43.
RosmanISBerkDRBaylissSJWhiteAJMerrittDF.Acute genital ulcers in nonsexually active young girls: case series, review of the literature, and evaluation and management recommendations. Pediatr Dermatol. 2012;29(2):147-153. doi:10.1111/j.1525-1470.2011.01589.x
44.
DixitSBradfordJFischerG.Management of nonsexually acquired genital ulceration using oral and topical corticosteroids followed by doxycycline prophylaxis. J Am Acad Dermatol. 2013;68(5):797-802. doi:10.1016/j.jaad.2012.10.014
45.
FemianoFBuonaiutoCGombosFLanzaACirilloN.Pilot study on recurrent aphthous stomatitis (RAS): a randomized placebo-controlled trial for the comparative therapeutic effects of systemic prednisone and systemic montelukast in subjects unresponsive to topical therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;109(3):402-407. doi:10.1016/j.tripleo.2009.10.024
46.
AndreaniSMRatnasinghamKDangHHGravanteGGiordanoP.Crohn’s disease of the vulva. Int J Surg. 2010;8(1):2-5. doi:10.1016/j.ijsu.2009.09.012
47.
FooWCPapalasJARobboySJSelimMA.Vulvar manifestations of Crohn’s disease. Am J Dermatopathol. 2011;33(6):588-593. doi:10.1097/DAD.0b013e31820a2635
48.
BhoyrulBLyonC.Crohn’s disease of the vulva: a prospective study. J Gastroenterol Hepatol. 2018;33(12):1969-1974. doi:10.1111/jgh.14291
49.
SartorRB.Mechanisms of disease: pathogenesis of Crohn’s disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol. 2006;3(7):390-407. doi:10.1038/ncpgasthep0528
50.
GargAHundalJStrunkA.Overall and subgroup prevalence of Crohn disease among patients with hidradenitis suppurativa: a population-based analysis in the United States. JAMA Dermatol. 2018;154(7):814-818. doi:10.1001/jamadermatol.2018.0878
51.
JennetteJCFalkRJBaconPAet al. 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis Rheum. 2013;65(1):1-11. doi:10.1002/art.37715
52.
TreudlerROrfanosCEZouboulisCC.Twenty-eight cases of juvenile-onset Adamantiades-Behçet disease in Germany. Dermatology. 1999;199(1):15-19. doi:10.1159/000018197
53.
KarincaogluYBorluMTokerSCet al. Demographic and clinical properties of juvenile-onset Behçet’s disease: a controlled multicenter study. J Am Acad Dermatol. 2008;58(4):579-584. doi:10.1016/j.jaad.2007.10.452
54.
Tugal-TutkunIUrganciogluM.Childhood-onset uveitis in Behçet disease: a descriptive study of 36 cases. Am J Ophthalmol. 2003;136(6):1114-1119. doi:10.1016/S0002-9394(03)00791-8
55.
Koné-PautIGeislerIWechslerBet al. Familial aggregation in Behçet’s disease: high frequency in siblings and parents of pediatric probands. J Pediatr. 1999;135(1):89-93. doi:10.1016/S0022-3476(99)70333-1
DireskeneliH.Behçet’s disease: infectious aetiology, new autoantigens, and HLA-B51. Ann Rheum Dis. 2001;60(11):996-1002. doi:10.1136/ard.60.11.996
58.
Criteria for diagnosis of Behçet’s disease. International Study Group for Behçet’s Disease. Lancet. 1990;335(8697):1078-1080.
59.
O’NeillTWRigbyASSilmanAJBarnesC.Validation of the International Study Group criteria for Behçet’s disease. Br J Rheumatol. 1994;33(2):115-117. doi:10.1093/rheumatology/33.2.115
60.
TaylorJGlennyAMWalshTet al. Interventions for the management of oral ulcers in Behçet’s disease. Cochrane Database Syst Rev. 2014;(9):CD011018. doi:10.1002/14651858.CD011018.pub2
61.
AlpsoyE.Behçet’s disease: treatment of mucocutaneous lesions. Clin Exp Rheumatol. 2005;23(4):532-539.
62.
AlpsoyEErHDurusoyCYilmazE.The use of sucralfate suspension in the treatment of oral and genital ulceration of Behçet disease: a randomized, placebo-controlled, double-blind study. Arch Dermatol. 1999;135(5):529-532. doi:10.1001/archderm.135.5.529
63.
YaziciHPazarliHBarnesCGet al. A controlled trial of azathioprine in Behçet’s syndrome. N Engl J Med. 1990;322(5):281-285. doi:10.1056/NEJM199002013220501
64.
HamuryudanVOzyazganYHizliNet al. Azathioprine in Behcet’s syndrome: effects on long-term prognosis. Arthritis Rheum. 1997;40(4):769-774. doi:10.1002/1529-0131(199704)40:4<769::AID-ART24>3.0.CO;2-E
65.
MelikogluMFreskoIMatCet al. Short-term trial of etanercept in Behçet’s disease: a double blind, placebo controlled study. J Rheumatol. 2005;32(1):98-105.
66.
MasudaKNakajimaAUrayamaANakaeKKogureMInabaG.Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet’s disease. Lancet. 1989;1(8647):1093-1096. doi:10.1016/S0140-6736(89)92381-7
67.
AlpsoyEDurusoyCYilmazEet al. Interferon alfa-2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study. Arch Dermatol. 2002;138(4):467-471. doi:10.1001/archderm.138.4.467
68.
AlikhanALynchPJEisenDB.Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol. 2009;60(4):539-561; quiz 562-563. doi:10.1016/j.jaad.2008.11.911
69.
JemecGB.Clinical practice. Hidradenitis suppurativa. N Engl J Med. 2012;366(2):158-164. doi:10.1056/NEJMcp1014163
70.
CosmatosIMatchoAWeinsteinRMontgomeryMOStangP.Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States. J Am Acad Dermatol. 2013;68(3):412-419. doi:10.1016/j.jaad.2012.07.027
71.
PrensEDeckersI.Pathophysiology of hidradenitis suppurativa: an update. J Am Acad Dermatol. 2015;73(5suppl 1):S8-S11. doi:10.1016/j.jaad.2015.07.045
72.
VazquezBGAlikhanAWeaverALWetterDADavisMD.Incidence of hidradenitis suppurativa and associated factors: a population-based study of Olmsted County, Minnesota. J Invest Dermatol. 2013;133(1):97-103. doi:10.1038/jid.2012.255
SchraderAMDeckersIEvan der ZeeHHBoerJPrensEP.Hidradenitis suppurativa: a retrospective study of 846 Dutch patients to identify factors associated with disease severity. J Am Acad Dermatol. 2014;71(3):460-467. doi:10.1016/j.jaad.2014.04.001
75.
ClemmensenOJ.Topical treatment of hidradenitis suppurativa with clindamycin. Int J Dermatol. 1983;22(5):325-328. doi:10.1111/j.1365-4362.1983.tb02150.x
76.
JemecGBWendelboeP.Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. J Am Acad Dermatol. 1998;39(6):971-974. doi:10.1016/S0190-9622(98)70272-5
77.
GenerGCanoui-PoitrineFRevuzJEet al. Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: a series of 116 consecutive patients. Dermatology. 2009;219(2):148-154. doi:10.1159/000228334
78.
ZhangJReederVJHamzaviIH.Use of biologics in the treatment of hidradenitis suppurativa: a review of the Henry Ford Hospital experience. Br J Dermatol. 2014;171(6):1600-1602. doi:10.1111/bjd.13186
79.
ChinniahNCainsGD.Moderate to severe hidradenitis suppurativa treated with biological therapies. Australas J Dermatol. 2014;55(2):128-131. doi:10.1111/ajd.12136
80.
MargessonLJDanbyFW.Hidradenitis suppurativa. Best Pract Res Clin Obstet Gynaecol. 2014;28(7):1013-1027. doi:10.1016/j.bpobgyn.2014.07.012
81.
DeFilippisEMFeldmanSRHuangWW.The genetics of pyoderma gangrenosum and implications for treatment: a systematic review. Br J Dermatol. 2015;172(6):1487-1497. doi:10.1111/bjd.13493
82.
González-MorenoJRuíz-RuigomezMCallejas RubioJLRíos FernándezROrtego CentenoN. Pyoderma gangrenosum and systemic lupus erythematosus: a report of five cases and review of the literature. Lupus. 2015;24(2):130-137. doi:10.1177/0961203314550227
83.
AlbertsJHSamsHHMillerJLKingLE.Familial ulcerative pyoderma gangrenosum: a report of 2 kindred. Cutis. 2002;69(6):427-430.
84.
KhandpurSMehtaSReddyBS.Pyoderma gangrenosum in two siblings: a familial predisposition. Pediatr Dermatol. 2001;18(4):308-312. doi:10.1046/j.1525-1470.2001.01936.x
AhronowitzIHarpJShinkaiK.Etiology and management of pyoderma gangrenosum: a comprehensive review. Am J Clin Dermatol. 2012;13(3):191-211. doi:10.2165/11595240-000000000-00000
87.
BennettMLJacksonJMJorizzoJLFleischerABWhiteWLCallenJP.Pyoderma gangrenosum. A comparison of typical and atypical forms with an emphasis on time to remission. Case review of 86 patients from 2 institutions. Medicine (Baltimore). 2000;79(1):37-46.
88.
SatohMYamamotoT.Genital pyoderma gangrenosum: report of two cases and published work review of Japanese cases. J Dermatol. 2013;40(10):840-843. doi:10.1111/1346-8138.12252
MadsenBSJensenHLvan den BruleAJWohlfahrtJFrischM.Risk factors for invasive squamous cell carcinoma of the vulva and vagina – population-based case-control study in Denmark. Int J Cancer. 2008;122(12):2827-2834. doi:10.1002/ijc.23446
91.
BuscemaJWoodruffJD.Progressive histobiologic alterations in the development of vulvar cancer. Am J Obstet Gynecol. 1980;138(2):146-150. doi:10.1016/0002-9378(80)90025-3
92.
SugiyamaVEChanJKShinJYBerekJSOsannKKappDS.Vulvar melanoma: a multivariable analysis of 644 patients. Obstet Gynecol. 2007;110(2pt 1):296-301. doi:10.1097/01.AOG.0000271209.67461.91
93.
de GiorgiVSalviniCMassiDRaspolliniMRCarliP.Vulvar basal cell carcinoma: retrospective study and review of literature. Gynecol Oncol. 2005;97(1):192-194. doi:10.1016/j.ygyno.2004.12.008
94.
MonteroAJDíaz-MonteroCMMalpicaARamirezPTKavanaghJJ.Langerhans cell histiocytosis of the female genital tract: a literature review. Int J Gynecol Cancer. 2003;13(3):381-388. doi:10.1046/j.1525-1438.2003.13204.x
95.
GroisNPötschgerUProschHet al. Risk factors for diabetes insipidus in Langerhans cell histiocytosis. Pediatr Blood Cancer. 2006;46(2):228-233. doi:10.1002/pbc.20425
96.
NewmanBHuWNigroKGilliamAC.Aggressive histiocytic disorders that can involve the skin. J Am Acad Dermatol. 2007;56(2):302-316. doi:10.1016/j.jaad.2006.06.010
